Characteristics | Patients (N=41) |
Age, years, median (range) | 64 (53–74) |
<65 | 21 (51.2) |
≥65 | 20 (48.8) |
Sex | |
Male | 35 (85.4) |
Female | 6 (14.6) |
ECOG performance status* | |
0 | 5 (12.2) |
1 | 35 (85.4) |
Smoking status* | |
Never | 12 (29.3) |
Current | 4 (9.8) |
Former | 24 (58.5) |
Histological type | |
Squamous carcinoma | 11 (26.8) |
Non-squamous carcinoma | 30 (73.2) |
Presence of metastases | 39 (95.1) |
Brain metastases | |
Yes† | 1 (2.4) |
No | 40 (97.6) |
Liver metastases | |
Yes | 3 (7.3) |
No | 38 (92.7) |
Any prior antitumor treatment‡ | 2 (4.9) |
PD-L1 TPS§ | |
1%–49% | 21 (51.2) |
≥50% | 20 (48.8) |
tTMB¶ | |
Low (<10 muts/Mb) | 15 (36.6) |
High (≥10 muts/Mb) | 12 (29.3) |
Data are n (%) unless otherwise indicated.
*Data missing for remaining patients.
†One patient, who had previously experienced brain metastases and undergone whole-brain radiotherapy, demonstrated radiographic evidence of stable disease for at least 1 month and exhibited no accompanying clinical symptoms. This patient met the eligibility criteria for enrolment.
‡Among the patients, one underwent curative lung cancer surgery followed by postoperative mediastinal radiotherapy and adjuvant therapy, achieving a recurrence-free interval of over 6 months post-therapy. Another patient had brain metastases and received whole-brain radiotherapy treatment.
§PD-L1 TPS was assessed per central laboratory testing. However, one patient was unevaluable due to the sample issues, and this patient had PD-L1 TPS of 80% per local assessment.
¶Mandatory fresh biopsy or archival tissue for tTMB was not requested at enrolment.
ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed death-ligand 1; TPS, tumor proportion score; tTMB, tissue tumor mutational burden; muts/Mb, mutations per megabase.